This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

This study has been withdrawn prior to enrollment.
(Study has been terminated due to lack of accrual.)
Sponsor:
Collaborator:
ImClone LLC
Information provided by:
Translational Drug Development
ClinicalTrials.gov Identifier:
NCT00954876
First received: July 17, 2009
Last updated: January 27, 2012
Last verified: January 2012
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: January 2010
  Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)